Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01487746|
Recruitment Status : Unknown
Verified December 2011 by Meir Medical Center.
Recruitment status was: Not yet recruiting
First Posted : December 7, 2011
Last Update Posted : December 7, 2011
The investigators expect to find higher levels of both classical and minor antiphospholipid (APL) antibodies among the stroke cases. Furthermore, the investigators expect to find not only classical APLA but also minor antibodies.
The investigators believe that minor antibodies have a major role in the hypercoagulability state.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||207 participants|
|Observational Model:||Case Control|
|Official Title:||Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls.|
|Study Start Date :||December 2011|
|Estimated Primary Completion Date :||March 2012|
|Estimated Study Completion Date :||September 2012|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01487746
|Contact: Yair Levy, Prof.||email@example.com,|
|Contact: Narin N Carmel, B.Scfirstname.lastname@example.org|
|Meir health center||Not yet recruiting|